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Abstract
Objectives: Specifically we aim to demonstrate that the results of our earlier safety data hold true in this much
larger multi-national and multi-ethnical population.
Background: We sought to re-evaluate the frequency, manifestations, and severity of acute adverse reactions
associated with administration of several gadolinium- based contrast agents during routine CMR on a European
level.
Methods: Multi-centre, multi-national, and multi-ethnical registry with consecutive enrolment of patients in 57
European centres.
Results: During the current observation 37788 doses of Gadolinium based contrast agent were administered
to 37788 patients. The mean dose was 24.7 ml (range 5–80 ml), which is equivalent to 0.123 mmol/kg (range
0.01 - 0.3 mmol/kg). Forty-five acute adverse reactions due to contrast administration occurred (0.12 %). Most
reactions were classified as mild (43 of 45) according to the American College of Radiology definition. The
most frequent complaints following contrast administration were rashes and hives (15 of 45), followed by
nausea (10 of 45) and flushes (10 of 45). The event rate ranged from 0.05 % (linear non-ionic agent gadodiamide) to
0.42 % (linear ionic agent gadobenate dimeglumine). Interestingly, we also found different event rates between the
three main indications for CMR ranging from 0.05 % (risk stratification in suspected CAD) to 0.22 % (viability in
known CAD).
Conclusions: The current data indicate that the results of the earlier safety data hold true in this much larger
multi-national and multi-ethnical population. Thus, the “off-label” use of Gadolinium based contrast in cardiovascular
MR should be regarded as safe concerning the frequency, manifestation and severity of acute events.
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Condensed abstract
We specifically aim to demonstrate that the results of our earlier safety data hold true in this much larger
multi-national and multi-ethnical population. During the current observation 37788 doses of Gadolinium based
contrast agent were administered to 37788 patients in a multi-centre, multi-national, and multi-ethnical setting
with consecutive enrolment of patients in 57 European centres. Forty-five acute adverse reactions due to
contrast administration occurred (0.12 %). Most reactions were classified as mild (43 of 45) according to the American
College of Radiology definition. Thus, the “off-label” use of Gadolinium based contrast in cardiovascular MR should be
regarded as safe concerning the frequency, manifestation and severity of acute events.
Background
In its early phase the EuroCMR Registry concluded in
2011 on the basis of 17767 mostly German pilot patients
[1] that the incidence of acute adverse reactions after
administration of Gadolinium based contrast in the “off-
label” setting of cardiovascular MR was not different to
the incidence of acute adverse reactions in the FDA
approved general radiology setting. Thus, on the basis of
this data the “off-label” use of Gadolinium based contrast
in cardiovascular MR was regarded as safe concerning the
frequency, manifestation and severity of acute events.
In the meantime more than 37000 consecutive patients
from 57 European centres in 15 countries have been in-
cluded in the EuroCMR Registry. With the current update
analysis we sought to re-evaluate the frequency, manifes-
tations, and severity of acute adverse reactions associated
with administration of several gadolinium- based contrast
agents of routine CMR on a European level. Specifically,
with this update we aim to demonstrate that the results of
our earlier safety data [1] hold true in this much larger
multi-national and multi-ethnical population.
Methods
Study population and data management
The current manuscript is based on data from the
EuroCMR registry including 11040 consecutive patients of
the German pilot phase (April 2007 and January 2009)
and 31031 patients of the on going European registry
(March 2009 - December 2014). All data were collected
prospectively using online case record forms provided by
the “Institut für Herzinfarktforschung Ludwigshafen”,
University of Heidelberg, Germany (www.herzinfarktfors
chung.de), as previously described [1–4]. The local ethics
committee approved all procedures with regard to data
collection and management. A senior cardiologist or radi-
ologist was appointed as local investigator and was re-
sponsible for the data quality of each patient entered in
the registry in every centre.
Analysis cohort
We included all patients receiving Gadolinium contrast
in the analysis (n = 37788, 90 % out of 42071 patients).
Gadolinium contrast was administered in compliance
with the current ACCF/ACR/SCCT/SCMR/ASNC/NAS
CI/SCAI/SIR appropriateness criteria for CMR [2–5].
The medical records of all patients suspected to have
suffered from an adverse event were reviewed centrally by a
group of authors serving as an end-point committee.
Variables and definitions
The EuroCMR Registry investigators collected pre-defined
variables directly from patients, and/or from medical re-
cords, such as demographic data, history, and indications
for CMR, procedural parameters, as well as complications
[2–4]. As in our previous dataset [1], all complications
caused by acute adverse reactions to contrast media (=
onset within 60 minutes after administration) were de-
fined according to the American College of Radiology
[6] criteria (Table 1).
Statistics
Senior statistician Steffen Schneider PhD, chair of the
Biometrics Department of the Institut für Herzinfarkt-
forschung, Ludwigshafen, Germany, performed the statis-
tical analysis. We described the distribution of the different
contrast media and the rate of adverse reactions in the pa-
tient population by absolute numbers and percentages.
Furthermore, medians (with ranges) and means (with
standard deviation) were calculated to describe the charac-
teristics of contrast media, as well as to characterize the pa-
tients with adverse reactions. Fisher’s exact test was used
to compare categorical parameters. Continuous variables
were compared by Wilcoxon rank-sum test. However, the
low rates of adverse events preclude most significance tests
and the absence of pre-specified statistical hypothesis in
the registry allows descriptive comparisons in most cases
only. All analyses were performed using the SAS statistical
package, version 9.3 (Cary, North Carolina).
Results
Acute adverse reactions by severity
The current dataset includes 37788 doses of Gadolinium
based contrast agent from different vendors, which were
administered to 37788 patients undergoing cardiovascular
MR in the participating centres of the EuroCMR Registry.
The mean dose was 24.7 ml (range 5–80 ml), which is
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equivalent to 0.123 mmol/kg (range 0.01 - 0.3 mmol/kg).
We observed 45 acute adverse reactions due to contrast
administration occurring during and immediately after the
CMR procedure (0.12 %). The rate of female patients in
the subgroup of the 45 patients suffering from adverse
reactions was 38 %, which was not significantly different
from the rate of females in the entire population (34 %).
Wilcoxon rank sum test could not reveal any relations
between acute reactions and the dose of Gadolinium
administered (p = 0.09). Most adverse reactions were clas-
sified as mild (Table 1), no moderate reactions were re-
corded and only two events were regarded as severe
reactions. There were no deaths due to contrast adminis-
tration (and no deaths due to CMR imaging), and we did
not observe an accumulation of events in a single centre
or a cluster of centres.
Acute adverse reactions by type of contrast media
Acute adverse reactions for the following contrast media
were evaluated by the EuroCMR Registry; Gadopentetate
(e.g. Magnevist), Gadoteracid (e.g. Dotarem), Gadobenat
(e.g. Multihance), Gadobutrol (e.g. Gadovist), Gadoteridol
(e.g. Prohance), Gadodiamide (e.g. Omniscan). All other
contrast media were summarized as “others”. Eighteen out
of the 57 centres exclusively used one single contrast
agent for all patients (Gadopentetate: n = 3, Gadoteracid:
n = 3, Gadobenat: n = 0, Gadobutrol: n = 8, Gadoteridol:
n = 2, Gadodiamide: n = 2). All other centres used at
least two or more different contrast agents in their clin-
ical routine.
All events categorised by severity and the specific con-
trast media can be viewed in Table 2. Between the differ-
ent agents the rate of adverse events ranged from 0.05 %
to 0.42 %. However, our data did not reveal any relation
between the event rates and the specific characteristics
of the different contrast agents, including structure or
chelate stability (p = 0.096), see Table 3.
Table 4 displays the characteristics of all patients with
acute adverse reactions by contrast agent. Complaints
after Gadolinium administration include rashes and hives
Table 1 Classification of severity and manifestation of adverse reactions to contrast media
Mild
Signs and symptoms appear self-limited without evidence of progression
(e.g., limited urticaria with mild pruritis, transient nausea, one episode of emesis) and include:
• Nausea, vomiting • Pallor
• Cough • Flushing
• Warmth • Chills
• Headache • Sweats
• Dizziness • Rash, hives
• Shaking • Nasal stuffiness
• Altered taste • Swelling: eyes, face
• Itching • Anxiety
Treatment: Requires observation to confirm resolution and/or lack of progression
and may require treatment in some cases. Patient reassurance is usually helpful.
Moderate
Signs and symptoms are more pronounced. Moderate degree of clinically evident focal or systemic signs or symptoms, including:
• Tachycardia/bradycardia • Bronchospasm, wheezing
• Hypertension • Laryngeal edema
• Generalized or diffuse erythema • Mild hypotension
• Dyspnea
Treatment: Clinical findings in moderate reactions frequently require prompt treatment.
These situations require close, careful observation for possible progression to a life-threatening event.
Severe
Sign and symptoms are often life-threatening, including:
• Laryngeal edema (severe or rapidly progressing) • Convulsions
• Profound hypotension • Unresponsiveness
• Clinically manifest arrhythmias • Cardiopulmonary arrest
Treatment: Requires prompt recognition and aggressive treatment; manifestations and treatment frequently require hospitalization.
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(15 of 45), followed by nausea (10 of 45) and flushes
(10 of 45). In the group of the 45 patients suffering
from adverse events, two suffered anaphylactic reactions
that were graded as severe events due to the combination
of bronchospasm and profound hypotension. Those two
patients were admitted as inpatients, and were initially
treated with adrenaline, steroids and antihistamines. Of the
remaining 43 patients suffering mild events 30 were admit-
ted for short-term observation, 16 of them were treated
with steroids and/or antihistamines as a precaution. All pa-
tients improved during treatment and could be discharged
later. No one except the two anaphylactic patients needed
to stay as inpatients due to the adverse contrast reaction.
Acute adverse events by CMR indication
Looking at all adverse reactions categorised by the initial
CMR indication, analysis revealed different event rates
for each of the three main indications [2–4]. The rate of
adverse reactions ranged from 0.05 % for the group of
mostly healthy individuals undergoing stress CMR for
risk stratification in suspected coronary artery disease to
0.22 % for patients undergoing non-stress CMR for work-
up of myocardial viability in the setting of known coronary
artery disease and heart failure (p = 0.001), (Table 5). Con-
sequently, more contrast related adverse events occurred
in the non-stress CMR group (e.g. evaluation of myocar-
dial viability) than in the stress CMR group (e.g. risk
stratification in suspected CAD), (p = 0.004).
Discussion
Just 45 of all 37788 patients included suffered from
Gadolinium related acute adverse reactions. Most reac-
tions were classified as mild, only two patients suffered
severe anaphylactic reactions, had to be admitted as inpa-
tients, and were initially treated with adrenaline, steroids
and antihistamines. All patients improved during treat-
ment, and could be discharged later. Our current dataset
confirms results of earlier safety data [1] in a much larger
multi-national, and multi-ethnical population, indicating
that the “off-label” use of Gadolinium based contrast in
cardiovascular MR should be regarded as safe concerning
the frequency, manifestation, and severity of acute events.
Cardiovascular MR in comparison to general radiology use
The relatively low number of patients not receiving con-
trast media in comparison to general radiology use is
most likely explained by the fact that for the three most
important CMR indications: 1) evaluation of ischemia,
2) evaluation of cardiomyopathy and myocarditis, 3)
evaluation of myocardial viability in CAD, the adminis-
tration of contrast is mandatory. According to earlier
EuroCMR Registry results more than 80 % of CMR scans
are ordered for one of those three indications [2, 4].
Our data demonstrate a rate of acute adverse reactions
of 0.12 %. This is even lower that in our previous dataset
[1] (0.12 % vs. 0.17 %), and also in line with the observa-
tions of the FDA approved general radiology use of
Gadolinium contrast, demonstrating a range of acute
adverse reactions from 0.04 % up to 2.2 % [7–15].
Importantly, mostly mild, no moderate, and only two
severe reactions occurred (Table 1), whereas other groups
reported up to 17.2 % of moderate [12], and up to 6.3 % of
severe reactions [12] in the general radiology setting.
Differences between groups
Event rates between the groups receiving different con-
trast agents ranged from 0.05 % to 0.42 %. This finding
also supports our previous report [1], and compares
favourably with the results of a retrospective analysis of
the FDA Adverse Event Reporting System [14]. One pos-
sible explanation for the different individual reaction rates
Table 2 Adverse Reactions Categorized by Severity and Agent
Agent N° of
Examinations
N° of Adverse Reactions
Mild Moderate Severe Total
Gadopentetat
(e.g. Magnevist)
12810 18 (0.14) 0 2 (0.02) 20 (0.16)
Gadoteracid
(e.g. Dotarem)
4235 5 (0.12) 0 0 5 (0.12)
Gadobenat
(e.g. Multihance)
706 3 (0.42) 0 0 3 (0.42)
Gadobutrol
(e.g. Gadovist)
9378 9 (0.1) 0 0 9 (0.10)
Gadoteridol
(e.g. Prohance)
1045 2 (0.19) 0 0 2 (0.19)
Gadodiamide
(e.g. Omniscan)
6116 3 (0.05) 0 0 3 (0.05)
Other 3498 3 (0.09) 0 0 3 (0.09)
Total 37788 43 (0.11) 0 2 (0.01) 45 (0.12)
Note - Values in parentheses are percentages
Table 3 Adverse Reactions Categorized by Agents Specific
Characteristics
Agent Molecular Structure I Ionic /
Non-Ionic
Log Ktherm Reactions
(%)
Gadopentetate
(e.g. Magnevist)
Linear Ionic 22.1 0.16
Gadoteracid
(e.g. Dotarem)
Cyclic Ionic 25.8 0.12
Gadobenat
(e.g. Multihance)
Linear Ionic 22.6 0.42
Gadobutrol
(e.g. Gadovist)
Cyclic Non-Ionic 21.8 0.10
Gadoteridol
(e.g. Prohance)
Cyclic Non-Ionic 23.8 0.19
Gadodiamide
(e.g. Omniscan)
Linear Non-Ionic 16.9 0.05
Others N/A N/A N/A N/A
Log Ktherm, chelate stability; N/A, non applicable
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Table 4 Patient Characteristics, Gadolinium Dose, and Characteristics of Reaction
All Gadopentetat
(Magnevist)
Gadoteracid
(Dotarem)
Gadobenat
(Multihance)
Gadotbutrol
(Gadovist)
Gadoteridol
(Prohance)
Gadodiamide
(Omniscan)
Other*
All 45 20 5 3 9 2 3 3
Age
(years, mean)
51.9 50.8 48.2 68.0 49.6 38.0 62.0 56.0
SD 16.5 18.1 19.0 4.6 16.1 14.1 4.0 13.0
Median 54.0 54.0 53.0 69.0 42.0 38.0 62.0 56.0
Range 16-
77
16-74 25-69 63-72 31-77 28-48 58-66 43-69
Sex
Male (%) 62.2 75.0 60.0 33.3 44.4 50 66.7 66.7
Contrast dose
(ml, mean)
20.6 22.5 24.8 13.7 13.2 14.3 20.0 23.0
SD 8.3 7.5 8.8 3.2 4.3 17.0 8.0 11.5
Median 20.0 22.5 28.0 15.0 14.0 28.0 20.0 27.0
Range 7-
40
7-36 10-32 10-16 10-21 16-40 12-28 10-32
Category of
reaction
Mild 43 18 5 3 9 2 3 3
Moderate 0 0 0 0 0 0 0 0
Severe 2 2 0 0 0 0 0 0
Symptoms
Allergic shock 2 2 0 0 0 0 0 0
Cardiac arrest 0 0 0 0 0 0 0 0
Dyspnoea 1 1 0 0 0 0 0 0
Bronchospasm 1 1 0 0 0 0 0 0
Nausea 10 3 0 1 2 0 2 2
Vomiting 6 3 0 0 0 0 2 1
Warmth 3 2 0 1 0 0 0 0
Headache 2 1 0 0 0 0 0 1
Dizziness 5 3 0 0 0 0 2 0
Altered taste 1 0 0 0 0 0 0 1
Itching 9 2 1 1 4 1 0 0
Flushing 10 2 1 1 6 0 0 0
Chills 2 1 0 0 1 0 0 0
Sweats 3 2 0 0 1 0 0 0
Rash/Hives 15 4 4 2 2 2 1 0
Swelling of
eye/face
1 1 0 0 0 0 0 0
Anxiety 6 6 0 0 0 0 0 0
Treatment
Observation 30 14 3 2 5 1 2 3
Antihistamines 18 4 3 2 4 1 3 1
Steroids 14 3 1 2 3 2 3 0
Adrenaline 2 2 0 0 0 0 0 0
*Dotarem is included in Other
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was suggested by Prince et al. [14]. The authors suspected
differences between the molecular structure and chelate
stability in the different agents as possible cause. However,
as displayed in Table 3 this does not seem to play a rele-
vant role for acute adverse reactions in our population
(p = 0.096). Nevertheless, parameters like structure and
chelate stability may have an effect on long-term com-
plications (e.g. nephrogenic systemic fibrosis). Unfortu-
nately, we do not have long-term follow-up data due
the limitations of the registry approach.
In addition, we found different reaction rates depend-
ing on the indication for CMR (see Table 5), as well as
when comparing groups of patients undergoing stress
CMR vs. non-stress CMR. As speculated earlier [1], this
finding is most likely explained by the different burden of
disease in the different patient groups. Whereas basically
healthy people undergoing stress CMR for risk stratifica-
tion of suspected coronary artery disease have the lowest
rate of adverse events, the in comparison sick group of
patients presenting with congestive heart failure for as-
sessment of myocardial viability in the setting of known
coronary artery disease has the highest rate of events.
On the basis of this finding, one may even speculate
that in this group some of the often unspecific symptoms
such as nausea or anxiety (see Tables 1 and 4), which had
been interpreted as Gadolinium related symptoms, may
also be due to the underlying disease (e.g. heart failure). In
fact, the reaction rate truly caused by Gadolinium itself
could be even lower than that currently reported.
Limitations
When interpreting registry data it is important to keep
in mind that a prospective randomized trial may be the
best tool to prove a certain principle, but only a registry
can reveal if the results of controlled trials hold true in the
multi-national multi-centre clinical routine [2]. Neverthe-
less, as in our previous manuscript [1], we can still only
provide data on acute reactions, since systematic long-
term follow-up (e.g. with regard to nephrogenic systemic
fibrosis (NSF)) is not available due to the registry structure
of the dataset. However, cases of NSF are not very likely
in our population, since all participating centres only
scanned patients after evaluation of renal function in
compliance with our registry protocol [2–4] and the
ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR ap-
propriateness criteria for CMR imaging [5].
Clinical implications
Our results demonstrate that our earlier safety data [1]
hold true in this much larger multi-national and multi-
ethnical population. Acute Gadolinium contrast related
complications are rare, and the event rate favourably
compares to that reported in the literature in a general
radiology setting [7–15]. Thus, it seems safe to assume
that the current “off-label use” of Gadolinium contrast
for CMR is not associated with an additional risk for pa-
tients. In fact, datasets such as the EuroCMR Registry may
help facilitating future FDA approval for Gadolinium in
the setting of CMR.
Conclusion
The current data indicate that the results of the earlier
safety data hold true in this much larger multi-national
and multi-ethnical population. Thus, the “off-label” use of
Gadolinium based contrast in cardiovascular MR should
be regarded as safe concerning the frequency, manifest-
ation and severity of acute events.
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Table 5 Adverse Reactions Categorized by Indication
All RS CAD MYO/CMP Viability
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(0,01%)
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(0,01%)
0/14106 (0%) 0/4037 (0%)
Mild 43/37788
(0,11%)
7/18840
(0,04%)
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(0,16%)
9/4037
(0,22%)
All 45/37788
(0,12%)
9/18840
(0,05%)
22/14106
(0,16%)
9/4037
(0,22%)
RS CAD, risk stratification in suspected coronary artery disease; MYO/CMP,
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myocardial viability in known coronary artery disease. See references 1- 4
for details
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